BOOK NOW & SAVE UP TO $600

9TH ANNUAL SUMMIT

WORLD BISPECIFIC

September 18-20, 2018
Boston, MA

www.bispecific.com

- **Validating Novel Applications**
- **Enhancing Product Developability**
- **Reverse Translating Clinical Insights**

30+ Expert Speakers:

David Poon
Executive Director, External Research & Development
Zymeworks

John Desjarlais
CSO
Xencor

Rakesh Dixit
VP, Research & Development
MedImmune

Jijie Gu
Head of Target Validation, Immunology Research
AbbVie

John Haurum
CEO
F-Star

Ercole Rao
Group Leader, Biologics Research, Engineered Protein Therapeutics
Sanofi

Eric Smith
Director
Regeneron

Janine Schuurman
Corporate VP, Research & Innovation
Genmab

Daniel Hofmann
Scientist
BioNTech

"The best conference in the bispecific field."
Bayer

Partners

applied biomath
revolutionizing drug invention

MabPlex

TRIANNI

hansonwade

Tel: +1 617 455 4188 **Email:** info@hansonwade.com
@Bispecific Bispecific Antibody Forum

Pioneering Novel Bispecific Applications Into The Clinic

Returning for the 9th time, the World Bispecific Summit is the definitive technical forum uniting leaders pioneering progress in this space.

Rather than vague platform overviews, this meeting will delve into novel applications of bispecific therapeutics, enabling you to realize the true potential of your pipeline.

More bispecifics are now in the clinic than ever before. Clearly there is real momentum behind the development of these therapeutics, however it's clear that their complexity continues to present a distinct set of challenges. Join your peers to discuss strategies to validate synergistic targets, streamline manufacturing and developability and maximize clinical performance.

This year **Novartis, Xencor, MedImmune, Regeneron** and **Pfizer** will be contributing fresh insights, lessons learned and clinical updates specifically geared towards enabling you to realize the potential of your bispecific candidates.

HEAR WHAT PREVIOUS ATTENDEES HAVE TO SAY:

"Focused on topics that matter. Top speakers. The best conference in the field in my opinion."
Glenmark

"An excellent opportunity to learn about the latest developments in the bispecific antibody field."
Boehringer Ingelheim

"Provides an excellent overview of the bispecifics field, and brings people of the field together for stimulating discussions and future research."
Roche

Brand New Content for 2018

1.

Target Solid Tumors Effectively
Understand how oncolytic vectors and the administration of mRNA encoding bispecifics can overcome delivery issues in effectively targeting solid tumors, with insights from **BioNTech's Daniel Hofmann**

2.

Dispel CMC Misconceptions
Zymeworks' Phil Hammond will share case studies detailing the rapid CMC development of bispecifics and repeatability of production at scales up to 3x2000L, demonstrating that the complexities of bispecific manufacturing should not be a limiting factor to progress

3.

Combine Checkpoint Pathways Effectively
With a series of checkpoint-targeting bispecifics nearing the clinic, **Xencor's John Desjarlais** will investigate the rationale and mechanistic understanding behind checkpoint-targeting, including an innovative triple blockade with a LAG3xCTLA4 bispecific plus PD-1 combination

4.

Pioneer Bispecifics Beyond Oncology
Understand the true potential of multispecific therapeutics in addressing challenges beyond oncology, by learning how the **NIH's Edward Berger** is developing bispecific CARs against HIV

5.

Investigate Strategic Business Decision-Making
As the commercial opportunities for bispecifics are starting to be realized, understand how **F-Star, Zymeworks** and **Biomunex** are fostering mutually beneficial collaborations with large pharma companies, through a dedicated focus evening

30+ Expert Speakers

Julian Andreev
Senior Staff Scientist
Regeneron

Edward Berger
Chief, Molecular Structure Section, Laboratory of Viral Diseases, NIAID
National Institutes of Health

John Blankenship
Senior Investigator & Lab Head, Therapeutic Antibody Discovery
Novartis

John Burke
President, CEO & Founder
Applied BioMath

Christian Cimander
Associate Director, CMC
Genmab

Igor D'Angelo
Senior Scientist & Team Lead, Antibody Engineering
Amgen

Jonathan Davis
Principal Scientist, Protein Design
Bristol-Myers Squibb

John Desjarlais
CSO
Xencor

Rakesh Dixit
VP, Research & Development
MedImmune

Pierre-Emmanuel Gerard
CEO
Biomunex

Christine Engeland
Cancer Researcher
National Center for Tumor Diseases

Matthias Friedrich
Scientific Director
Amgen

Changshou Gao
Senior Director & Fellow
MedImmune

Dragan Grabulovski
CEO & Founder
Grabulovski Consulting Services

Jijie Gu
Head of Target Validation, Immunology Research
AbbVie

Phil Hammond
Director, Therapeutics Preclinical Development
Zymeworks

John Haurum
CEO
F-Star

Daniel Hofmann
Scientist
BioNTech

Andrea Hooper
Associate Director, Targeted Immunotherapy, Targeted Therapeutics Discovery
Pfizer

Laura Jeanbart
Research Project Leader, Biology
Molecular Partners

Wibke Lembke
Associate Director Development
Covagen, one of the Biopharmaceutical Companies of Johnson & Johnson

David Poon
Executive Director, External Research & Development
Zymeworks

Jonathan Lai
Associate Professor
Albert Einstein College of Medicine

Robert Mabry
VP, Protein Science
Cogen Therapeutics

Krzysztof Masternak
Head of Biology
NovImmune

Paul Moore
VP, Cell Biology & Immunology
MacroGenics

Ercole Rao
Group Leader, Biologics Research, Engineered Protein Therapeutics
Sanofi

Janine Schuurman
Corporate VP, Research & Innovation
Genmab

Laura von Schantz
Senior Scientist
Alligator Bioscience

Eric Smith
Director
Regeneron

Krzysztof Wicher
Principal Scientist & Group Leader
Ossianix

"Excellent presentations covering a good spread of approaches and technologies!"
MedImmune

Pre-Conference Workshop Day | Tuesday, September 18

Workshop A

Choose A or B

Blood-Brain Barrier Crossing Biologics: Current Status, Future Potential & Challenges in Developing These Therapeutics? | Time: 9.00am – 12.00pm

Developing blood-brain barrier (BBB) crossing therapeutics is challenging, but the potential rewards for success are huge, given the unmet need currently in a range of neurological diseases. An increasing amount of evidence suggests that by using efficient delivery methods, such as Trojan-horse shuttles, bispecific antibodies and other biologics can effectively cross the BBB, providing an interesting and novel application for these technologies.

Gain valuable insights into:

- Diseases of CNS that can be addressed by BBB-crossing bispecific therapeutics
- Challenges faced when developing bispecific products to cross the BBB
- The current landscape of the field: How advanced are BBB-crossing bispecifics and what are most promising strategies?

Workshop Leader

Krzysztof Wicher, Principal Scientist & Group Leader, **Ossianix**

Workshop B

Investigating Immune Modulation Through Bispecifics – How Can We Select Rational Designs? | Time: 9.00am – 12.00pm

Multispecific formats clearly demonstrate opportunities to achieve a greater efficacy than combinations of individual mAbs in engaging the immune system, including targeting checkpoint modulating targets. Investigating the underlying biology of the indication and how designs can incorporate this is essential in establishing target combinations to create effective immuno-oncology therapeutics.

Address key challenges including:

- Our mechanistic understanding of checkpoint inhibition to guide future targeting strategies
- How bispecifics can add most value in modulating the immune system
- Explore case studies detailing the synergistic effects of bispecific targeting

Workshop Leader

Paul Moore, VP, Cell Biology & Immunology, **MacroGenics**

Workshop C

Choose C or D

Investigating Approaches to Enable the Patient's Body to Synthesise Bispecific Constructs by Administering DNA or mRNA Encoding the Therapeutic | Time: 1.00pm – 4.00pm

The clinical development of novel bispecific approaches has no doubt been hindered by a variety of developability and delivery challenges. Innovative novel approaches aim to address this issue by administering mRNA or DNA encoding the bispecific construct, enabling the patient's body to produce the therapeutic.

Gain valuable insights into:

- The unique challenges posed by developing and administering mRNA or DNA encoding bispecifics
- Understanding the true benefits and future applications of this approach
- Investigating preclinical evidence supporting these approaches and the issues that still need to be overcome

Workshop Leader

Daniel Hofmann, Scientist, **BioNTech**

Workshop Leader

Christine Engeland, Cancer Researcher, **National Center for Tumor Diseases**

Workshop D

Bioanalytical Strategy for Bispecifics: Beyond Classical PK & Immunogenicity Assessment
Time: 1.00pm – 4.00pm

Analyzing anti-drug-antibody (ADA) responses and the integrity of your bispecific format is of paramount importance in the preclinical and clinical development of any bispecific antibody. The selection of the right bioanalytical tools is a key consideration of this process.

Key highlights include:

- Evaluate key considerations when assessing the bioanalytical strategy
- Compare the pros and cons of different ADA assays
- Discuss different pharmacokinetic assays

Workshop Leader

Dragan Grabulovski, CEO & Founder, **Grabulovski Consulting Services**

Workshop Leader

Wibke Lembke, Associate Director Development, **Covagen, one of the Biopharmaceutical Companies of Johnson & Johnson**

Conference Day One | Wednesday, September 19

7.30 Registration & Networking

Janine Schuurman
Genmab

8.20 Chair's Opening Remarks

8.30 Challenges & Opportunities in Development of Bispecifics and Combination Biology

Rakesh Dixit
VP, Research & Development
MedImmune

- Understanding the importance of bispecifics as therapeutics in high unmet medical needs human diseases
- Evaluating the challenges involved in bispecific target selection, effector or ADC enhanced format selection, CMC and overall developability challenges
- Assessing the clinical pipeline of bispecifics and success rates
- Looking ahead: What is the future of the bispecific field?

9.00 Bispecific Technology for Multiple Avenues of T-Cell Activation

John Desjarlais
CSO
Xencor

- Investigating checkpoint bispecifics to improve therapeutic index: PD1 x CTLA4
- Developing triple checkpoint blockade: LAG3 x CTLA4 bispecific plus anti-PD1
- Checkpoint plus costim: PD1 x ICOS
- Potency-tuned IL15 for prolonged T-Cell stimulation

9.30 Model Aided Drug Invention (MADI) Case Studies in Research: In Silico Differentiation for Dual Targeting PD-1 and Tim-3 in I/O, & Predicting Optimal Drug Properties of a Bispecific Biologic to Maximize Tissue Targeting in OA

John Burke
President, CEO & Founder
Applied BioMath

- IMADI is a rigorous fit-for-purpose model development process which aims to quantitatively integrate knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms
- Exploring two case studies that highlight examples of MADI efforts that have de-risked projects, accelerated the discovery and development of best-in-class therapeutics, and impacted critical decisions, in the continuum from preclinical exploration to clinical research
- Integrating systems modeling to predict optimal drug properties targeting PD-1 and TIM3 in immuno-oncology for bispecific biologics and fixed dose combinations
- Investigating MADI approaches to determine best in class properties for targeted anabolic growth factor to arthritic joints

10.00 Speed Networking & Morning Refreshments

DISCOVERY TRACK

Identifying & Validating Novel Targets Effectively

Track Chair: Jonathan Davis, Principal Scientist, Protein Design, **Bristol-Myers Squibb**

11.30 Engineering Bispecific Antibodies to Match Target & Disease Biology: ABT-165 (dilpacimab) as a Case Study

- ABT-165 is a bispecific antibody targeting DLL4 and VEGF with multiple distinct MOAs
- ABT-165 was uniquely engineered to match target and disease biology with the consideration of efficacy, safety and developability
- ABT-165 demonstrated favorable in vivo efficacy, pharmacokinetic and safety profiles in pre-clinical models, and currently is being investigated in Phase II clinical studies for the treatment of solid tumors

Jijie Gu, Head of Target Validation, Immunology Research, **AbbVie**

DEVELOPMENT TRACK

Laying the Foundations for Clinical Success Through Rational Early Development Strategies

Track Chair: Robert Mabry, VP, Protein Science, **Cogen Therapeutics**

11.30 Understanding the True Value of Combinations of In Silico and In Vitro Analytical Approaches for Bispecifics

- Highlighting the diverse array of modelling approaches to characterize mechanism of action and therapeutic window
- Utilizing next generation sequencing to guide in silico work
- Case study: Antibody engineering guided by computer simulation in the development of a therapeutic targeting the CGRP receptor

Igor D'Angelo, Senior Scientist & Team Lead, Antibody Engineering, **Amgen**

12.00 Validating Target With Biologies Amenable to Bispecific Targeting: CD47 Case Study
- Understanding CD47 as an immune checkpoint controlling both the innate and the adaptive immune responses
- Highlighting how the blockade of tumor-expressed CD47 with bispecific antibodies promotes tumor cell phagocytosis, antigen cross-presentation, and T-Cell mediated immunity
- Investigating how bispecific antibodies allow selective blockade of the ubiquitously expressed CD47 on tumor cells, representing an advantage in terms of drug pharmacology and safety as compared to CD47 targeting monoclonal antibodies

Krzysztof Masternak, Head of Biology, **NovImmune**

12.00 Engineering functional and developable TNFRS bispecific antibodies
- Talk details to be confirmed

Laura von Schantz, Senior Scientist, **Alligator Bioscience**

12.30 Lunch & Networking

Discovering Innovative Bispecific Formats to Address Specific Biological Challenges

1.30 Development of T-Cell Redirecting Fully Human Bispecific Antibodies
- Bispecific antibodies are a promising new class of molecules for treatment of a variety of oncology indication
- Regeneron's lead bispecific antibody REGN1979 (CD20xCD3) has entered clinical testing and shows promising activity in Phase 1 studies
- REGN4018, a first in class Muc16xCD3 bispecific antibody, has completed pre-clinical evaluation and has entered clinical development this year

Eric Smith, Director, **Regeneron**

2.00 Extended Q&A

Enhancing the Effectiveness of BiTE Therapeutics

1.30 Preclinical Characterization of BiTE® Antibody Constructs for the Treatment of Cancer
- Understanding approaches to validate new BiTE constructs preclinically to lay a robust path to the clinic
- Toxicological assessments for bispecific constructs
- Evolving the BiTE platform to improve half-life

Matthias Friedrich, Scientific Director, **Amgen**

2.00 Utilizing Oncolytic Vectors to Augment the Efficacy of BiTE Therapeutics Against Solid Tumors
- Understanding the delivery challenges involved in targeting solid tumors
- Developing oncolytic vectors as delivery vehicles to target direct on-tumor effects
- Analyzing the advantages of this approach in solving delivery challenges and enhancing the effects of bispecifics

Christine Engeland, Cancer Researcher, **National Center for Tumor Diseases**

2.30 Afternoon Refreshments & Poster Viewing

Improving the Developability of Bispecifics

Phil Hammond
Director, Therapeutics Preclinical Development
Zymeworks

3.30 Rapid CMC Development of Different Formats of Bispecifics Using Traditional Up- and Down-Stream Methods
- Generating bispecifics using a number of industry-standard cell-line development approaches
- Highlighting scalability and repeatability of bispecific production at scales of up to 3x2000L
- Showcasing the rapid CMC development of a number of bispecific formats through case studies
- Demonstrating that approaches in CMC development and corresponding manufacturing costs of bispecifics is comparable to traditional monoclonal antibodies

Christian Cimander
Associate Director, CMC
Genmab

4.00 Showcasing Effective CMC Development for Bispecific Antibodies
- Dispelling misconceptions about the complexities and challenges involved in developing and manufacturing bispecifics
- Applying platform-based approaches for developability assessment as well as for development and manufacture
- Highlighting streamlined approach from DNA to FIH GMP manufacturing processes
- Case studies detailing CMC approaches in the development of a range of bispecific therapeutics

Janine Schuurman
Genmab

4.30 Chair's Closing Remarks

Conference Day One | Focus Evening

Focus Evening – Strategic Business Considerations in Developing and Commercializing Bispecifics

More bispecifics are reaching late stage clinical development than ever before, and it's clear that significant investments continue to be made to collaboratively advance these therapeutics.

To align with this trend, this evening deep-dive evening shifts the focus from the technical to the strategic, analysing the current state of the bispecifics business landscape to ensure you're set to make strategic decisions with greater confidence in the coming months.

Hosted By:

Dragan Grabulovski
CEO & Founder
Grabulovski Consulting Services

Dr. Dragan Grabulovski was previously chief scientific officer and co-founder of Covagen AG, a Swiss biotech company acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. As Covagen's CSO, he was responsible for developing and overseeing the execution of the overall strategy for research and development. As a member of Covagen's executive management team, Dr. Grabulovski was instrumental in Covagen's trade sale to Johnson & Johnson, and in the closing of Covagen's CHF 45M ($44.5M) Series B round in 2014 with the participation of renowned investors such as GIMV, Edmond de Rothschild Investment Partners, Novartis Venture Fund and other prestigious funds.

5.15 Chair's Opening Remarks

David Poon
Zymeworks

Pierre-Emmanuel Gerard
Biomunex

John Haurum
F-Star

5.30 Panel Discussion: Analysing Deal Structures and their Impact on the Bispecific Space

- Understanding how elements of deals such as exclusivities actually work
- Investigating how closely commercial collaborations and deals are tied to research
- Fostering mutually beneficial collaborations and deals between small biotechs and large pharmaceutical companies

6.15 Mastermind Discussion Groups

This collaborative exercise will enable you to collectively discuss the commercialization of bispecifics. Gain insights and perspectives from colleagues at various stages of development in the field and benchmark your progress against a variety of companies and organizations.

6.45 Chair's Closing Remarks

"Great speakers, great networking and stimulating discussions!"
Sanofi

"I was able to talk directly with top pioneers in bispecific antibody technologies."
Mitsubishi Tanabe

Conference Day Two | Thursday September 20

8.30 Registration & Networking

Janine Schuurman
Genmab

8.50 Chair's Opening Remarks

Jonathan Lai
Associate Professor
Albert Einstein College of Medicine

9.00 Bispecific Antibodies as Immunotherapies Against Emerging Viruses

- Bispecific antibodies harbor great potential as novel immunotherapeutics for emerging viruses
- Mitigating against viral escape through the multiepitope targeting using bispecific antibodies
- Engineering bispecific antibodies using structure-based design

Pierre-Emmanuel Gerard
CEO
Biomunex

9.30 Producing Next-Generation Bi- and Multispecific Antibodies for the Immunotherapy of Cancer Using the BiXAb® Platform

- Leveraging the power of immune checkpoint inhibition by targeting of PD-L1 and CD38 with the BMX-101 BiXAb®
- Simultaneously increasing activity with a synergistic combination of immune modulatory activities associated with anti-CD38 and anti-PD-L1 moieties and reducing the side effects
- Inhibiting the tumor microenvironment and reversing disease-mediated "immune paralysis"
- Increasing potency and efficacy relative to monospecific antibodies while improving safety and QoL of R/R MM patients

Andrea Hooper
Associate Director, Targeted Immunotherapy, Targeted Therapeutics Discovery
Pfizer

10.00 Talk Details to be Confirmed

10.30 Morning Refreshments & Networking

Developing Innovative Multispecific Therapeutics to Address the Unique Challenges Posed by HIV

Ercole Rao
Group Leader, Biologics Research, Engineered Protein Therapeutics
Sanofi

11.00 Pioneering a Novel Bispecific Format Enabling the Generation of Flexible Bi- and Trispecific Therapeutics

- Understanding how flexibility can enable the modulation of PK and PD
- Case studies detailing applications including CD3/CD123 targeting and an HIV approach
- Investigating trispecific approaches to increase the proportion of antigens neutralized

Edward Berger
Chief, Molecular Structure Section, Laboratory of Viral Diseases, NIAID
National Institutes of Health

11.30 Bispecific CARs against HIV: Shared and Unique Challenges for HIV versus Cancer

- Moving Target(s)
- Hit the Bad Guys Only
- Location, Location, Location
- The Functional Duration Problem

12.00 Lunch & Networking

Enhancing the Safety & Efficacy of Next Generation Bispecifics

Changshou Gao
Senior Director & Fellow
MedImmune

1.00 Modulating Bispecific Epitopes & Affinities to Enhance Safety and Efficacy

- Understanding the importance of epitopes and bispecific architectures to increase efficacy
- Modulating affinities to improve targeting selectivity and engage targets more effectively
- Overcoming the key challenges to develop next generation biologics successfully

John Blankenship
Senior Investigator & Lab Head, Therapeutic Antibody Discovery
Novartis

1.30 Talk Details to be Confirmed

2.00 Afternoon Refreshments & Networking

Pioneering Novel Approaches to Achieve Tumor Specificity

Julian Andreev
Senior Staff Scientist
Regeneron

2.30 Bispecific ADCs Bridging HER2 & Constitutively Internalizing Proteins Improve Efficacy of HER2 ADCs

- Rapid constitutive turnover of PRLR is the mechanism behind PRLR ADC efficacy
- Bridging constitutively internalizing proteins with HER2 using bispecific antibodies, HER2 lysosomal degradation can be triggered and HER2 ADC efficacy can be significantly improved
- Exploiting high turnover proteins in combination with bispecific antibodies to enhance efficacy of ADCs

Laura Jeanbart
Research Project Leader, Biology
Molecular Partners

3.00 Targeting and Modulating the Tumor Microenvironment with Multispecific DARPin® Therapeutics

- MPAG is developing bi- and multi-specific therapeutic DARPin® molecules to address some of the limitations of current cancer treatments
- MP0250 is a first-in-class dual VEGF and HGF antagonist with the potential to modulate the tumor microenvironment and enable increased activity of standard of care therapies and the breaking of resistance
- MP0310 is a multispecific DARPin® therapeutic that activates immune cells in a localized, tumor-specific manner, by simultaneously engaging a TNF superfamily receptor and binding to a tumor target

Janine Schuurman
Genmab

3.30 Chair's Closing Remarks

"The World Bispecific Summit is a critical, focussed conference that brings together the leaders in a field that represents the frontiers of the next generation of therapeutic biologics!"
Lathrop & Gage LLP

JOIN THE WORLD BISPECIFIC COMMUNITY

Engage directly with the experts pioneering the bispecifics field

As the only event to focus exclusively on bispecifics, the World Bispecific Summit is able to offer a greater breadth and depth of technical content than any other conference.

This niche focus also means that you can be sure all the attendees you'll meet are facing similar challenges to you, enabling you to engage with you in **relevant and constructive conversations**.

Interactive sessions built into the main agenda provide extensive opportunities for cross-functional collaboration. This meeting will enable you to benchmark your progress and critically evaluate your bispecific development approach.

Leave with clear and actionable insights that will significantly enhance your bispecific development.

ATTENDEE COMPANY TYPE

33% Pharma
39% Biotech
9% Academic
16% Solution Provider
3% Other

ATTENDEE GEOGRAPHY



75% North America
15% Europe
10% Asia

*Statistics based on World Bispecific 2017

PAST ATTENDEES INCLUDE

abbvie, Ablynx, Alexion, Alligator Bioscience, Amgen, Avitide, Baxalta, Bayer HealthCare, Biogen, Daiichi-Sankyo, Lilly, EMD Serono, emergent biosolutions, F-star Bispecific. By Design., FivePrime, Fortress Biotech, Genentech, GenScript, Gilead, Glenmark, GlaxoSmithKline, ImmunoGen, Johnson & Johnson, MacroGenics, MaxCyte, MedImmune, Merrimack, Merus, Novo Nordisk, OncoMed Pharmaceuticals, Pfizer, Regeneron, Rigel, Roche, Stemcentrx, Tesaro, UCB, WuXi AppTec, zymeworks

Tel: +1 617 455 4188 Email: info@hansonwade.com
www.bispecific.com @Bispecific Bispecific Antibody Forum

hansonwade

PARTNERSHIP OPPORTUNITIES

Are you front of mind when biopharma companies look externally for assistance in the development of bispecifics?

Bispecific approaches continue to emerge as important and commercially valuable therapeutic options, a trend that has been demonstrated clearly by the recent investments in this space by companies like Sanofi, Seattle Genetics and Janssen.

The 9th Annual World Bispecific Summit will bring together key decision makers from these companies, as well as host of other industry leading pharma and biotech organizations, who are actively seeking collaborators to overcome challenges in developing the next generation of bispecific therapeutics.

Act now to stay ahead of the curve and seize the wealth of opportunity on offer.

Get in touch today for more information about the bespoke partnership opportunities available.

"I got a great overview of bispecifics and what they are utilized for. I talked to companies that want to use our instrument for transient material. It was a great conference for me."
Maxcyte

"This meeting gave me clear ideas for how we can take our platform to the next level."
Kymab

BECOME A PARTNER

Rob Keast
Partnership Manager
T. +44 (0)20 3141 8700
E. sponsor@hansonwade.com

PARTNERS

applied biomath
revolutionizing drug invention

Expertise Partner

Applied BioMath applies mechanistic modeling to drug R&D to help biotechnology and pharmaceutical companies answer complex, scientific questions and make critical decisions for the advancement of drug candidates. A team of mathematicians, biologists, clinical pharmacologists and pharmaceutical industry experts, they leverage biology, mathematics, proprietary technologies, HPC, and industry experience to perform massive scale simulations which enable groups to determine best-in-class properties of a clinical candidate, reduce attrition rates, and identify key differentiators from competitors.

www.appliedbiomath.com

MabPlex

Event Partner

MabPlex International provides one-stop, high-quality CRO/CMO solutions for biologics (mAb and ADCs) to our global clients. We are dedicated to help our clients accelerate development process and reduce manufacture costs. MabPlex has extensive experiences in manufacturing for therapeutic antibodies and antibody-drug conjugates (ADCs). Our manufacturing facilities with large-scale disposable lines and world-class instruments are operated by well-trained professionals in full compliance with U.S, European, and Chinese GMP regulations.

www.mabplex.com

TRIANNI

Event Partner

Trianni, Inc. is a biotech company specializing in human antibody discovery platform technology. Our existing asset is a cutting-edge platform enabling efficient discovery of fully-human monoclonal antibodies. The Trianni Mouse offers biologic drug discoverers a best-in-class solution for the isolation therapeutic antibody candidates. Benefits over older conventional mouse immunization + humanization approaches include superior lead panels with respect to potency and diversity along with speed to the clinic and lower operating costs.

ww.trianni.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.bispecific.com/register

Tel: +1 617 455 4188

Email: register@hansonwade.com

1. More bispecifics-focussed presentations than any other conference
2. Engage directly with the industry leading pharma and biotech companies in an intimate environment
3. Understand how to overcome key discovery and developmental challenges to realize the clinical potential of bispecifics

SECURE YOUR PLACE

Package Details	Register & Pay by Friday, May 25	Standard Pricing
Gold: Conference & 2 Workshops	$3597 **(save $600)**	$3997 **(save $200)**
Silver: Conference & 1 Workshop	$2998 **(save $500)**	$3398 **(save $100)**
Bronze: Conference Only	$2399 **(save $400)**	$2799
Workshops - Individual	$699	

Academics are entitled to 40% off the drug developer prices. Use code "ACA" when registering online.

"Highly interactive conference with excellent presentations and exciting data."
Ablynx

Team Discounts

- **15% discount – 3 delegates**
- **20% discount – 4 + delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

VENUE

Wydham Boston Beacon Hill
5 Blossom St, Boston, MA 02114, USA

For further information or assistance, please visit www.wyndhambeaconhill.com

Code: 9708